Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Danaher Corporation
DHR
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $137.2B
$197.93
▲ +2.17%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$160.93 - $242.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 4.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diverse technology portfolio
- Strong R&D capabilities
- Global market presence
- Proven acquisition strategy
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Increasing biotech research investments
Value
Attractively priced below Life Sciences Tools peer average
Momentum
Stable
+1.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
Modest
0.74% yield
Smart-money signal
Who's buying DHR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 20, 2026
APR 21, 2026
Reported EPS of $2.06 vs $1.94 consensus (+6.2% surprise). Revenue of $6.0B vs $6.0B expected (-0.5%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+6.2%
Next: Apr 20, 2026
Revenue trend · last 8Q
—
—
+2%
-1%
+3%
+4%
+5%
+4%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$5.7B
$5.8B
$6.5B
$5.7B
$5.9B
$6.1B
$6.8B
$6.0B
Margins · last 8Q
Gross
60.3%
Operating
22.6%
Profit
17.3%
Wall Street consensus
13 analysts · 77% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
77%
Hold
23%
Sell
0%
Median Price Target
$230.00
▲ +16.2% vs $197.93
Latest: Piper Sandler · Jun 11, 2026
6 analysts covering